For PD-1/PD-L1 inhibitor–related PNS, current treatment generally consists of discontinuing immune checkpoint inhibitors (ICIs), while adopting individualized immunomodulatory regimens including corticosteroids, intravenous immunoglobulin, plasma exchange, anti–tumor necrosis factor-α antibodies, tacrolimus, methotrexate, cyclophosphamide, interleukin-17 inhibitors, or rituximab (12, 13). The gene discussed is PDCD1; the disease is paraneoplastic neurologic syndrome.